Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
NCT07207408Phase 2Active, not recruiting
- Sponsor
- Dynavax Technologies
- Start
- Sep 2025
- Primary completion
- Jan 2027
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of rF1V vaccine + CpG 1018 in pneumonic plague, sponsored by Dynavax Technologies. Started Sep 2025; status: active, not recruiting.
02
Drugs
rF1V vaccine + CpG 1018
03
Conditions
pneumonic plague
Beyond the preview
Go deeper on NCT07207408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07207408.